Benitec Biopharma Inc.(BNTC)

$11.04—

Ask SA Chart

Benitec Biopharma Inc.(BNTC)

NASDAQ

$11.04—

Ask SA Chart Studio

BNTC(BNTC)

BNTC

Q4 2026 EPS Estimate

$-0.27

Nov 13, 2026 · Reports before open

FY2031E EPS$0.21

Analyst Sentiment

Wall St. Consensus

Buy

8 analysts·Limited coverage

Score

7 Buy (88%)1 Hold (13%)0 Sell (-1%)

Rating Breakdown

Strong Buy

00%

Buy

788%

Hold

113%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$17.00

+50.8%

Consensus

$21.00

+86.3%

Bull

$25.00

+121.8%

12-Month Target Range8 analysts

$17.00$21.00$25.00

Current $11.27Consensus

Current Price

$11.27

Upside to Consensus

$9.73

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-14.03%

EPS—

FY2028

Rev+225.25%

EPS—

FY2029

Rev+84.32%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2027E	FY2028E	FY2029E	FY2030E	FY2031E
Revenue Avg	$22M	$71M	$131M	$27M	$149M
Low	$22M	$71M	$131M	$27M	$149M
High	$22M	$71M	$131M	$27M	$149M
EBITDA Avg	$-52M	$-65M	$-60M	$-68M	$15M
Low	$-61M	$-65M	$-64M	$-68M	$15M
High	$-44M	$-65M	$-56M	$-68M	$15M
EBIT Avg	$-53M	$-66M	$-62M	$-70M	$13M
Low	$-61M	$-66M	$-66M	$-70M	$13M
High	$-45M	$-66M	$-58M	$-70M	$13M
Net Income Avg	$-53M	$-66M	$-62M	$-70M	$10M
Low	$-61M	$-66M	$-66M	$-70M	$10M
High	$-45M	$-66M	$-58M	$-70M	$10M
EPS Avg	$-1.13	$-1.42	$-1.33	$-1.50	$0.21
Low	$-1.31	$-1.42	$-1.41	$-1.50	$0.21
High	$-0.96	$-1.42	$-1.25	$-1.50	$0.21
Analysts (Rev / EPS)	6 / 3	3 / 1	3 / 2	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	—	—	$9M	$27M	—	—
Low	—	—	$9M	$27M	—	—
High	—	—	$9M	$27M	—	—
EBITDA Avg	—	—	$-14M	$-15M	—	—
Low	—	—	$-14M	$-15M	—	—
High	—	—	$-14M	$-15M	—	—
EBIT Avg	—	—	$-14M	$-15M	—	—
Low	—	—	$-14M	$-15M	—	—
High	—	—	$-14M	$-15M	—	—
Net Income Avg	$-12M	$-14M	$-14M	$-15M	$-18M	$-19M
Low	$-12M	$-14M	$-14M	$-15M	$-18M	$-19M
High	$-12M	$-13M	$-14M	$-15M	$-18M	$-19M
EPS Avg	$-0.26	$-0.29	$-0.30	$-0.32	$-0.38	$-0.41
Low	$-0.26	$-0.30	$-0.30	$-0.32	$-0.38	$-0.41
High	$-0.25	$-0.27	$-0.30	$-0.32	$-0.38	$-0.41
Analysts (Rev / EPS)	— / 2	— / 2	1 / 1	1 / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Sep 15, 2026Wedbush

Benitec Biopharma price target raised to $17 from $16 at Wedbush

Target:$17.00

+44.9%from $11.73

Jul 28, 2026Wedbush

Benitec Biopharma initiated with an Outperform at Wedbush

Target:$16.00

+38.2%from $11.58

May 12, 2026Evercore ISI

Benitec Biopharma initiated with an Outperform at Evercore ISI

Target:$25.00

+108.2%from $12.01

Nov 24, 2025H.C. Wainwright

Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright

Target:$32.00

+141.3%from $13.26

Nov 4, 2025H.C. Wainwright

Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright

Target:$35.00

+123.1%from $15.69

Nov 4, 2025JMP Securities

Benitec Biopharma price target raised to $22 from $20 at Citizens JMP

Target:$22.00

+38.7%from $15.86

Sep 16, 2025Oppenheimer

Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer

Target:$29.00

+112.3%from $13.66

Oct 14, 2024JMP Securities

Benitec Biopharma price target raised to $18 from $16 at JMP Securities

Target:$18.00

+65.7%from $10.86

Oct 14, 2024JMP Securities

Benitec Biopharma price target lowered to $16 from $18 at JMP Securities

Target:$16.00

+47.3%from $10.86

Oct 14, 2024Leerink Partners

Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC)

Target:$13.00

+19.7%from $10.86

Sep 24, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)

Target:$30.00

+237.8%from $8.88

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance